Taysha Gene Therapies Stock Fundamentals
| TSHA Stock | USD 1.93 0.05 2.66% |
Taysha Gene Therapies fundamentals help investors to digest information that contributes to Taysha Gene's financial success or failures. It also enables traders to predict the movement of Taysha Stock. The fundamental analysis module provides a way to measure Taysha Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taysha Gene stock.
At present, Taysha Gene's Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 6 M, whereas Selling General Administrative is forecasted to decline to about 26.5 M. Taysha | Select Account or Indicator |
Taysha Gene Therapies Company Return On Equity Analysis
Taysha Gene's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Taysha Gene Return On Equity | -1.15 |
Most of Taysha Gene's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taysha Gene Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Taysha Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Taysha Gene Therapies has a Return On Equity of -1.1477. This is 95.21% lower than that of the Biotechnology sector and 96.85% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Taysha Gene Therapies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taysha Gene's current stock value. Our valuation model uses many indicators to compare Taysha Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taysha Gene competition to find correlations between indicators driving Taysha Gene's intrinsic value. More Info.Taysha Gene Therapies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Taysha Gene's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taysha Gene's earnings, one of the primary drivers of an investment's value.Taysha Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taysha Gene's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics of similar companies.Taysha Gene is currently under evaluation in return on equity category among its peers.
Taysha Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of Taysha Gene from analyzing Taysha Gene's financial statements. These drivers represent accounts that assess Taysha Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Taysha Gene's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 468.8M | 438.6M | 99.3M | 205.5M | 236.4M | 462.5M | |
| Enterprise Value | 217.6M | 352.6M | 71.4M | 122.7M | 141.1M | 134.1M |
Taysha Fundamentals
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 290.14 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 77.16 % | ||||
| Number Of Shares Shorted | 21.88 M | ||||
| Price To Book | 4.34 X | ||||
| Price To Sales | 39.89 X | ||||
| Revenue | 15.45 M | ||||
| Gross Profit | 2.5 M | ||||
| EBITDA | (105.2 M) | ||||
| Net Income | (111.57 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 61.11 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (73.02 M) | ||||
| Short Ratio | 3.66 X | ||||
| Earnings Per Share | 0.63 X | ||||
| Target Price | 6.59 | ||||
| Number Of Employees | 52 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 395.54 M | ||||
| Total Asset | 172.73 M | ||||
| Retained Earnings | (513.01 M) | ||||
| Working Capital | 113.11 M | ||||
| Net Asset | 172.73 M |
About Taysha Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 16.3 M | 20.7 M | |
| Total Revenue | 17.8 M | 18.7 M | |
| Cost Of Revenue | 1.6 M | 1.2 M | |
| Stock Based Compensation To Revenue | 0.59 | 0.56 | |
| Sales General And Administrative To Revenue | 2.24 | 2.12 | |
| Research And Ddevelopement To Revenue | 4.23 | 4.01 | |
| Capex To Revenue | 0.55 | 0.52 | |
| Revenue Per Share | 0.12 | 0.08 | |
| Ebit Per Revenue | (4.22) | (4.43) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Taysha Gene Piotroski F Score and Taysha Gene Altman Z Score analysis. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.